Aarti Industries Ltd (AARTIIND) Q3FY25 Concall Summary - Dec-2024 Qtr
Performance Overview
- Aarti Industries Ltd. (AIL) reported sequential EBITDA improvement in Q3 FY25, driven by strong volume growth, cost efficiencies, product diversification, and geographic expansion.
- Pricing pressures, particularly in agrochemical intermediates, impacted margins.
- Non-energy business volumes grew 14% Y-o-Y and 8% Q-o-Q.
- Energy business volumes grew 10% Q-o-Q, with a large bulk shipment spilling over to Q4.
- Inventory levels for agrochemicals have normalized.
- AIL is developing new products within the ethylation value chain and pursuing backward integration for select downstream products.
- Polymer and additives business is recovering, and AIL aims to increase market share in the U.S. and Japan.
- Pharma business continues its positive trajectory.
- In the energy business, AIL is diversifying its MMA solution offerings and customer base.
- Weak gasoline and naphtha cracks in Q3 impacted octane boosting economics, but improvement is anticipated in Q4.
- AIL has established bulk shipment capabilities for MMA and is expanding its customer base in the U.S., Europe, and the Middle East.
- Two renewable energy power purchase agreements were signed, targeting >75% renewable power by Q1 FY27.
- A joint venture with Re Sustainability and Recycling Private Limited (RESL) aims to establish a plastic material recycling facility with a target capacity of 500 tons per day by 2030.
- Revenue for Q3 FY25 was INR 2,035 crore, up 14% Q-o-Q and 8% Y-o-Y.
- EBITDA grew 17% Q-o-Q to INR 236 crore.
- PAT was INR 46 crore, impacted by a forex mark-to-market loss of INR 23 crore.
- Projected capital expenditure for FY25 remains at INR 1,300 crore to INR 1,500 crore.
- Key capacity expansions include nitrotoluene (30 to 45 KTPA) and ethylation (8-10 KTPA to 25-30 KTPA) facilities.
- MMA capacity expansion to 200 KTPA is complete.
- Zone IV projects are progressing with phased commissioning expected through FY26.
- AIL is on track to meet its short-term and medium-term guidance, targeting 20%-25% EBITDA CAGR over 3-5 years.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.